CAR T-cell Therapy for Extramedullary Multiple Myeloma: from Early Response to Durable Disease Control

Ziyi Yang, Mi Zhou, Yi Xiao · 2026

Read CAR T-cell Therapy for Extramedullary Multiple Myeloma: from Early Response to Durable Disease Control by Ziyi Yang, Mi Zhou, Yi Xiao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13354695.txt.

Description

Ziyi Yang and colleagues comment on why CAR T-cell therapy often fails to hold in extramedullary multiple myeloma, in a 2026 piece. Disease outside the marrow should count as high-risk biology, not a mere variant of relapse. The key split is paraskeletal spread, which stays near bone, versus true extraosseous disease, which travels through blood and signals marrow escape.

BCMA-directed CAR T cells can shrink relapsed myeloma fast, yet patients with active extraosseous disease respond less often and progress sooner than those without it. Pooling the two forms, the authors warn, inflates how durable cell therapy looks for the patients who need help most. The comment calls for separate reporting and trials aimed at the extramedullary niche.

Catalog record

CREATORZiyi Yang, Mi Zhou, Yi Xiao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE9 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13354695

Browse the full library · About the Tower of Babel